<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477100</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1072</org_study_id>
    <secondary_id>NCI-2018-01784</secondary_id>
    <secondary_id>2006-1072</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00477100</nct_id>
  </id_info>
  <brief_title>Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer</brief_title>
  <official_title>Inflammatory Breast Cancer (IBC) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the biospecimen and medical data collection in creating a research tissue
      registry in patients with inflammatory or invasive breast cancer. Collecting medical data and
      storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to
      study in the laboratory may help doctors find better ways to treat and study inflammatory
      breast cancer in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To prospectively collect tissue (including primary inflammatory breast cancer [IBC],
      ipsilateral nodal metastasis and/or distant metastasis [if applicable] obtained prior to
      primary systemic therapy and mastectomy/axillary dissection), serum, plasma, whole blood,
      clinical, and imaging data from patients with recently diagnosed inflammatory breast cancer
      (IBC), or highly suspicious for IBC, who have not received systemic therapy.

      II. To collect paraffin tissue blocks or unstained slides (including primary, ipsilateral
      nodal metastasis and/or distant metastasis [if applicable] obtained prior to primary systemic
      therapy), mastectomy/axillary dissection tissue, serum, plasma, whole blood, clinical, and
      imaging data (if available) from patients with previously diagnosed inflammatory breast
      cancer (IBC), who have been treated or partially treated, but have not had mastectomy and are
      seeking further treatment in the IBC clinic at M. D. Anderson or participating cancer network
      sites.

      III. To collect oral swab, skin and stool bacterial culture swab for microbiome analysis to
      compare patients with specific breast cancer subtype to report changes in flora during the
      course of treatment and correlated to toxicity.

      OUTLINE:

      Patients complete questionnaires and participate in interview over 30 minutes. Patients also
      undergo collection of medical data and blood, tissue, and stool samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2007</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Data, serum, tissue, peripheral blood mononuclear cells, and plasma sample collection</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>No statistical considerations are provided. For each clinical question that will use the data collected in this registry, a separate protocol will be submitted to the Institutional Review Board (IRB) that will include a sample size justification and an analysis plan.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Inflammatory Breast Carcinoma</condition>
  <condition>Invasive Breast Carcinoma</condition>
  <condition>Second Primary Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
    <description>Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood, tissue, and stool</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Participate in interview</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Undergo collection of medical data</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Observational (biospecimen and medical data collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tissue, stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with inflammatory or invasive breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second
             primary IBC, or highly suspicious for IBC (MD Anderson patients only).

          -  Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD
             Anderson patients only) but pending breast cancer diagnosis.

          -  Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only)
             [Cohort I] or have paraffin blocks or up to 20 unstained slides of each representative
             block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy)
             and/or from mastectomy (Cohort II-MD Anderson patients only)

          -  Age &gt; 18 years

          -  Able to provide informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto T Ueno</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Willey</last_name>
    <phone>713-792-3965</phone>
    <email>jwilley@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-2817</phone>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Katy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto T. Ueno</last_name>
      <phone>713-792-8754</phone>
      <email>nueno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naoto T. Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

